Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2023-07-31 Director's Dealing
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as an 'Insider Trading Report' or 'Director's Dealing' report) where company insiders disclose changes in their shareholdings. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2023-07-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific director (Son Byong Kwan) of SCM Lifescience. This type of filing is a standard regulatory requirement for insider trading or changes in ownership by company executives, which corresponds to the 'Director's Dealing' category.
2023-07-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, specifically regarding the allocation and trading of new share subscription rights due to a rights offering. This falls under the category of Major Shareholding Notification (MRQ).
2023-07-31 Korean
유상증자1차발행가액결정(주주배정후 실권주 일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from SCM Lifescience regarding the determination of the '1st issue price' for a paid-in capital increase (rights offering). This falls under the category of capital structure changes and financing activities, specifically related to share issuance pricing. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most appropriate category for announcements regarding new share issues and capital changes.
2023-07-10 Korean
[기재정정]주요사항보고서(유무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from SCM Lifescience Co., Ltd. regarding a decision on capital increase (both paid-in and bonus issues). It details the correction of the issue price for a previously announced capital increase. This type of filing, which details changes to share issuance, capital structure, and subscription terms, falls under the 'Share Issue/Capital Change' category.
2023-07-10 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It details a capital increase (rights offering) and specifically announces the finalization of the issuance price (1차발행가액 확정). This is a formal regulatory filing required for public offerings of securities. It is not a report publication announcement (RPA) because it contains the substantive details of the offering itself, nor is it a simple RNS. It fits the 'Regulatory Filings' category as it is a formal, mandatory filing with a regulatory body regarding securities issuance.
2023-07-10 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.